Welcome!

News Feed Item

Entia Biosciences Secures Michael J. Fox Foundation Grant

SHERWOOD, OR -- (Marketwired) -- 07/14/14 -- Entia Biosciences Inc. (OTCQB: ERGO), an emerging leader in the field of nutrigenomics, has been awarded a grant by The Michael J. Fox Foundation for Parkinson's Research to conduct a preclinical study of its ErgoD2® medical food formulation as a potential therapy for Parkinson's disease (PD). This study is the second and final in a series of planned studies conducted by Entia utilizing a transgenic murine model developed by Dr. Robert Nussbaum. The first study was successfully conducted in collaboration with Dr. Jack Rogers, PhD, at the Massachusetts General Hospital Neurochemistry Laboratory, in which ErgoD2® was shown to increase muscle strength and reduce the toxic buildup of midbrain alpha-synuclein levels. The newly commissioned study has been expanded to measure brain iron levels, key brain biomarkers, as well as, alpha-synuclein levels -- an approach that aims to provide insight into the overall physiologic system of the disease, which may prove invaluable in further substantiating ErgoD2's future role in the treatment and/or prevention of PD.

Parkinson's is a chronic progressive movement disorder characterized by shaking and difficulties with walking, movement, and coordination. The causes of PD are yet unknown, however, several risk factors have been identified, among which are alpha-synuclein and iron overload in the brain. Alpha-synuclein protein is increased in PD and its toxic form contributes to progressive neurodegeneration of nerve cells that produce dopamine, a chemical that helps regulate movement and muscle coordination. Iron accumulation in these neurons can also contribute to neurodegeneration in PD, because increased intracellular iron is associated with oxidative stress and neuro-inflammation, both of which, in turn, perpetuate the disease.

Entia's ErgoD2® technology aims to slow PD progression by stabilizing iron levels, reducing inflammation, and boosting the internal antioxidant system. At the core of this technology are L-Ergothioneine and Ergocalciferol, which, in previous clinical studies conducted by Entia in diabetes and chronic kidney disease, have been shown to stimulate iron export from the cell. These findings are now being applied to PD as a way to reduce the iron burden inside the degenerating dopamine-producing cells. The resulting reduction in intracellular iron levels is hypothesized to mitigate the associated inflammation and oxidative stress in the PD brain, thereby slowing degeneration of nerve cells. This systems-level approach -- designed by Entia Biosciences -- will also be applied in future clinical studies, in which ErgoD2® will be evaluated for its impact on various biological indicators of health and disease.

"We are grateful and excited to be working with The Michael J. Fox Foundation," said Dr. Marvin Hausman, MD., Chairman and CEO of Entia Biosciences Inc. "To date, the small molecule, drug development approach to this complex problem has not yielded a viable therapy. We believe that the overall health of the body, and the genetically required nutrients found in ErgoD2®, may be playing a major role in regulating the onset and/or progression of neurodegenerative and other debilitating diseases. With the Foundation's support, we intend to validate this hypothesis and accelerate the availability of our ErgoD2® medical food to the millions of people who suffer from or are at-risk for developing PD." Additional information about the grant and the study's objectives can be found at: https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1341

About ErgoD2®

ErgoD2® is a proprietary pharmaceutical grade organic compound from whole food that contains the micro-nutrients L-Ergothioneine, an amino acid with a dedicated transporter (SLC22A4), and Ergocalciferol (vitamin D2). These nutrients are naturally enhanced and concentrated to therapeutic levels using Entia's patented technology.

About Entia Biosciences, Inc.

Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture. www.entiabio.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2013 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, will provide economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session will also include a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
IoT generates lots of temporal data. But how do you unlock its value? You need to discover patterns that are repeatable in vast quantities of data, understand their meaning, and implement scalable monitoring across multiple data streams in order to monetize the discoveries and insights. Motif discovery and deep learning platforms are emerging to visualize sensor data, to search for patterns and to build application that can monitor real time streams efficiently. In his session at @ThingsExpo, ...
Ixia (Nasdaq: XXIA) has announced that NoviFlow Inc.has deployed IxNetwork® to validate the company’s designs and accelerate the delivery of its proven, reliable products. Based in Montréal, NoviFlow Inc. supports network carriers, hyperscale data center operators, and enterprises seeking greater network control and flexibility, network scalability, and the capacity to handle extremely large numbers of flows, while maintaining maximum network performance. To meet these requirements, NoviFlow in...
Choosing the right cloud for your workloads is a balancing act that can cost your organization time, money and aggravation - unless you get it right the first time. Economics, speed, performance, accessibility, administrative needs and security all play a vital role in dictating your approach to the cloud. Without knowing the right questions to ask, you could wind up paying for capacity you'll never need or underestimating the resources required to run your applications.
Security, data privacy, reliability and regulatory compliance are critical factors when evaluating whether to move business applications from in-house client hosted environments to a cloud platform. In her session at 18th Cloud Expo, Vandana Viswanathan, Associate Director at Cognizant, In this session, will provide an orientation to the five stages required to implement a cloud hosted solution validation strategy.
"delaPlex is a software development company. We do team-based outsourcing development," explained Mark Rivers, COO and Co-founder of delaPlex Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
ReadyTalk has expanded the capabilities of the FoxDen collaboration platform announced late last year to include FoxDen Connect, an in-room video collaboration experience that launches with a single touch. With FoxDen Connect, users can now not only engage in HD video conferencing between iOS and Android mobile devices or Chrome browsers, but also set up in-person meeting rooms for video interactions. A host’s mobile device automatically recognizes the presence of a meeting room via beacon tech...
Ovum, a leading technology analyst firm, has published an in-depth report, Ovum Decision Matrix: Selecting a DevOps Release Management Solution, 2016–17. The report focuses on the automation aspects of DevOps, Release Management and compares solutions from the leading vendors.
Continuous testing helps bridge the gap between developing quickly and maintaining high quality products. But to implement continuous testing, CTOs must take a strategic approach to building a testing infrastructure and toolset that empowers their team to move fast. Download our guide to laying the groundwork for a scalable continuous testing strategy.
On Dice.com, the number of job postings asking for skill in Amazon Web Services increased 76 percent between June 2015 and June 2016. Salesforce.com saw its own skill mentions increase 37 percent, while DevOps and Cloud rose 35 percent and 28 percent, respectively. Even as they expand their presence in the cloud, companies are also looking for tech professionals who can manage projects, crunch data, and figure out how to make systems run more autonomously. Mentions of ‘data science’ as a skill ...
Adding public cloud resources to an existing application can be a daunting process. The tools that you currently use to manage the software and hardware outside the cloud aren’t always the best tools to efficiently grow into the cloud. All of the major configuration management tools have cloud orchestration plugins that can be leveraged, but there are also cloud-native tools that can dramatically improve the efficiency of managing your application lifecycle. In his session at 18th Cloud Expo, ...
SYS-CON Events announced today that LeaseWeb USA, a cloud Infrastructure-as-a-Service (IaaS) provider, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. LeaseWeb is one of the world's largest hosting brands. The company helps customers define, develop and deploy IT infrastructure tailored to their exact business needs, by combining various kinds cloud solutions.
Amazon has gradually rolled out parts of its IoT offerings in the last year, but these are just the tip of the iceberg. In addition to optimizing their back-end AWS offerings, Amazon is laying the ground work to be a major force in IoT – especially in the connected home and office. Amazon is extending its reach by building on its dominant Cloud IoT platform, its Dash Button strategy, recently announced Replenishment Services, the Echo/Alexa voice recognition control platform, the 6-7 strategic...
Up until last year, enterprises that were looking into cloud services usually undertook a long-term pilot with one of the large cloud providers, running test and dev workloads in the cloud. With cloud’s transition to mainstream adoption in 2015, and with enterprises migrating more and more workloads into the cloud and in between public and private environments, the single-provider approach must be revisited. In his session at 18th Cloud Expo, Yoav Mor, multi-cloud solution evangelist at Cloudy...
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...